Quotient Clinical, a provider of specialist early-stage drug development services, and Capsugel, a provider of dosage solutions for the healthcare industry, announced a collaboration to enable the rapid development and clinical assessment of lipid-based formulations. Together, the companies will use their technology and expertise to address the drug delivery challenges of poorly soluble molecules with limited oral bioavailability.
The collaboration integrates Quotient's RapidFACTTM real-time clinical manufacture and testing service with Capsugel's lipid-based formulation and manufacturing capability. With up to 70% of the industry's development pipeline consisting of molecules with poor solubility, the collaboration will aim to fast track the effective clinical evaluation of lipid-based drug delivery systems in man, while optimizing the drug product for downstream development.
As part of the collaboration, Quotient will use Capsugel's CFS Liquid Capsule Filling and Sealing technology at its facility in Nottingham, U.K. and will be able to access the formulation expertise in Capsugel's Development Centre in Strasbourg.
Mark Egerton, managing director of Quotient Clinical, says, "The collaboration with Capsugel will help our customers address prevalent drug-delivery challenges for poorly soluble compounds in a more effective way. It will further empower our RapidFACT service by ensuring that selected drug products can be rapidly scaled-up and transitioned into downstream development-further reducing timelines to critical development milestones."
Capsugel's knowledge of capsules and Licaps™ liquid filling and sealing technology helps to speed up the development process.
More information is available on Quotient Clinical.
More information is available onQuotient Bioresearch.
The collaboration integrates Quotient's RapidFACTTM real-time clinical manufacture and testing service with Capsugel's lipid-based formulation and manufacturing capability. With up to 70% of the industry's development pipeline consisting of molecules with poor solubility, the collaboration will aim to fast track the effective clinical evaluation of lipid-based drug delivery systems in man, while optimizing the drug product for downstream development.
As part of the collaboration, Quotient will use Capsugel's CFS Liquid Capsule Filling and Sealing technology at its facility in Nottingham, U.K. and will be able to access the formulation expertise in Capsugel's Development Centre in Strasbourg.
Mark Egerton, managing director of Quotient Clinical, says, "The collaboration with Capsugel will help our customers address prevalent drug-delivery challenges for poorly soluble compounds in a more effective way. It will further empower our RapidFACT service by ensuring that selected drug products can be rapidly scaled-up and transitioned into downstream development-further reducing timelines to critical development milestones."
Capsugel's knowledge of capsules and Licaps™ liquid filling and sealing technology helps to speed up the development process.
More information is available on Quotient Clinical.
More information is available onQuotient Bioresearch.
